Medtronic reported Q2 FY25 revenue of $8.4 billion, up 5.3% as reported and 5.0% organic. GAAP diluted EPS was $0.99, while non-GAAP diluted EPS reached $1.26. The company raised its FY25 organic revenue growth guidance to 4.75-5% and non-GAAP EPS guidance to $5.44-$5.50.Strong performance was seen across multiple franchises, including TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation. The Cardiovascular Portfolio grew 6.1% as reported, Neuroscience Portfolio increased 7.1%, and Diabetes revenue rose 12.4%. Medical Surgical Portfolio saw modest growth of 1.2%.Medtronic Chairman and CEO Geoff Martha highlighted the company's building momentum and execution on commitments. The company's focus on innovation and diversified growth, coupled with underlying margin improvement, is expected to drive high-single digit constant currency adjusted EPS growth in the second half of the fiscal year.

Medtronic reported Q2 FY25 revenue of $8.4 billion, up 5.3% as reported and 5.0% organic. GAAP diluted EPS was $0.99, while non-GAAP diluted EPS reached $1.26. The company raised its FY25 organic revenue growth guidance to 4.75-5% and non-GAAP EPS guidance to $5.44-$5.50.Strong performance was seen across multiple franchises, including TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation. The Cardiovascular Portfolio grew 6.1% as reported, Neuroscience Portfolio increased 7.1%, and Diabetes revenue rose 12.4%. Medical Surgical Portfolio saw modest growth of 1.2%.Medtronic Chairman and CEO Geoff Martha highlighted the company's building momentum and execution on commitments. The company's focus on innovation and diversified growth, coupled with underlying margin improvement, is expected to drive high-single digit constant currency adjusted EPS growth in the second half of the fiscal year.